Gilead closed its $7.8 billion acquisition of Arcellx in April, paying $115 a share in cash plus a $5 contingent value right tied to $6 billion in future sales of anito-cel, the BCMA-directed CAR-T therapy it was really buying. A week later, Gilead disclosed it’s cutting 192 jobs. Arcellx had 220 employees. That’s 87% of the workforce, gone, for a company Gilead just spent nearly $8 billion to own outright.
The pattern isn’t unique to Gilead. BioNTech’s $1.25 billion all-stock buyout of CureVac, which closed in December, is now shedding 820 people from CureVac’s German and international sites by the end of 2027. Novartis’s $1.4 billion Tourmaline Bio deal cost 60 New York jobs. BioMarin’s $4.8 billion all-cash purchase of Amicus Therapeutics is cutting 58 heads in Princeton.
Here’s the buyer math: once the acquirer has the asset, it doesn’t need the org chart. Gilead wanted anito-cel’s regulatory pathway and manufacturing, not Arcellx’s HR department or facilities lease. Five M&A-linked deals this year alone have wiped out at least 1,130 jobs, on top of a broader 14,427-person layoff tally across biopharma in H1 2026.
Takeda’s transformation program runs on different math: 4,500 cuts funding drug launches, with no acquisition involved.
M&A-driven layoffs should keep climbing as more of 2026’s roughly 52 announced deals close their integration phase.
— Diana Kowalski